Search Results

You are looking at 91 - 100 of 237 items for :

  • "neoadjuvant chemotherapy" x
Clear All
Full access

J. Sybil Biermann, Douglas R. Adkins, Robert S. Benjamin, Brian Brigman, Warren Chow, Ernest U. Conrad III, Deborah A. Frassica, Frank J. Frassica, Suzanne George, Kenneth R. Hande, Francis J. Hornicek, G. Douglas Letson, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Neeta Somaiah and Alan W. Yasko

neoadjuvant chemotherapy in cooperative study group protocols, axial tumor site, male gender, and a long history of symptoms were associated with poor response to chemotherapy. Patient age and tumor location at diagnosis had a significant influence on outcome

Full access

Raymond Jang, Gail Darling and Rebecca K.S. Wong

carcinoma . Chin Med J (Engl) 2013 ; 126 : 3138 – 3145 . 15. Kumagai K Rouvelas I Tsai JA . Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable

Full access

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns and Miranda Hughes

chemotherapy followed by interval cytoreduction remains controversial for epithelial ovarian cancer. 94 – 101 Neoadjuvant chemotherapy may be considered (category 1) for patients with bulky stage III to IV disease who are not surgical candidates; however, a

Full access

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, Rachel Clark, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian and Jillian L. Scavone

greater cervical cancers. Abroad, select FIGO IB2 to IIB cases may be treated with radical hysterectomy or neoadjuvant chemotherapy followed by radical hysterectomy. For recurrent or persistent cervical cancers that are confined to the central pelvis (ie

Full access

Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes and Douglas E. Wood

tolerate the toxicities of cisplatin, no data are available to adequately guide therapy. A total of 755 patients were treated in 11 trials assessing neoadjuvant chemotherapy, and 627 patients were treated in 11 trials assessing concurrent CRT. The overall

Full access

Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Vicki Keedy, Edward Kim, Henry Koon, Joel Mayerson, Martin McCarter, Sean V. McGarry, Christian Meyer, Zachary S. Morris, Richard J. O'Donnell, Alberto S. Pappo, I. Benjamin Paz, Ivy A. Petersen, John D. Pfeifer, Richard F. Riedel, Bernice Ruo, Scott Schuetze, William D. Tap, Jeffrey D. Wayne, Mary Anne Bergman and Jillian L. Scavone

associated with a major survival benefit for patients with high-grade tumors. 71 Histotype-specific neoadjuvant chemotherapy was examined in a recent international randomized controlled trial of patients with high-risk STS (n=287; ISG-STS, 1001). 72

Full access

Philippe E. Spiess, Simon Horenblas, Lance C. Pagliaro, Matthew C. Biagioli, Juanita Crook, Peter E. Clark, Richard E. Greenberg and Cesar E. Ercole

standard ILND approach should be adopted if nodal metastases are detected on frozen section. Traditionally, a standard lymphadenectomy has been offered for resectable metastatic ILNs, although recent data would support neoadjuvant chemotherapy followed by

Full access

Carol D. Morris

Biol Phys 2005 ; 61 : 492 – 498 . 10 Machak GN Tkachev SI Solovyev YN . Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities . Mayo Clin Proc 2003 ; 78 : 147 – 155 . 11 Anderson P

Full access

Ronan J. Kelly

be added as one of the chemotherapy regimens to be assessed in the main study. In total, 860 patients will be randomized to 3 cycles of neoadjuvant chemotherapy plus either pembrolizumab or placebo followed by surgery, and then in the adjuvant setting

Full access

Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama and Manisha Palta

delivery of >20 total fractions. Start dates for neoadjuvant chemotherapy and radiation had to be within 30 days to ensure concurrent delivery. CRT was considered neoadjuvant if surgery occurred <180 days after radiation start. AC was defined as